Suppr超能文献

mRNA-1273 或 Omicron 加强针在接种疫苗的猕猴中引发相似的 B 细胞扩增、中和反应,并提供针对 Omicron 的保护。

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.

机构信息

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA.

出版信息

Cell. 2022 Apr 28;185(9):1556-1571.e18. doi: 10.1016/j.cell.2022.03.038. Epub 2022 Mar 25.

Abstract

SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing titers against D614G were 4,760 and 270 reciprocal ID at week 6 (peak) and week 41 (preboost), respectively, and 320 and 110 for Omicron. 2 weeks after the boost, titers against D614G and Omicron increased to 5,360 and 2,980 for mRNA-1273 boost and 2,670 and 1,930 for mRNA-Omicron, respectively. Similar increases against BA.2 were observed. Following either boost, 70%-80% of spike-specific B cells were cross-reactive against WA1 and Omicron. Equivalent control of virus replication in lower airways was observed following Omicron challenge 1 month after either boost. These data show that mRNA-1273 and mRNA-Omicron elicit comparable immunity and protection shortly after the boost.

摘要

SARS-CoV-2 的奥密克戎变体传播性很强,并且对基于原始刺突蛋白匹配疫苗的免疫具有很强的抗性。目前尚不清楚使用奥密克戎匹配疫苗进行加强免疫是否会增强保护效果。在这项研究中,接受了 0 周和 4 周 mRNA-1273 接种的非人类灵长类动物在第 41 周时使用 mRNA-1273 或 mRNA-Omicron 进行了加强免疫。第 6 周(峰值)和第 41 周(预加强)时,针对 D614G 的中和滴度分别为 4760 和 270 倒数 ID,针对奥密克戎的中和滴度分别为 320 和 110。加强免疫后 2 周,针对 D614G 和奥密克戎的滴度分别增加到 mRNA-1273 加强免疫的 5360 和 2980,mRNA-Omicron 的 2670 和 1930。针对 BA.2 的中和滴度也观察到了类似的增加。在接受任何一种加强免疫后,70%-80%的刺突特异性 B 细胞对 WA1 和奥密克戎具有交叉反应性。在加强免疫后 1 个月,奥密克戎挑战后下呼吸道的病毒复制得到了类似的控制。这些数据表明,mRNA-1273 和 mRNA-Omicron 在加强免疫后不久会产生相当的免疫和保护效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/3f57e3f3c87a/fx1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验